AltrixBio
Lowell, Massachusetts, United States · Biotechnology, Health Care · 7 employees
AltrixBio is a biopharmaceutical company pioneering treatments for cardiometabolic diseases. The company focuses on innovative therapies for type 2 diabetes and metabolic disorders. AltrixBio aims to transform the treatment landscape through its cutting-edge research and development. With a commitment to bringing novel therapies to patients, AltrixBio is at the forefront of metabolic health.
Funding history
- Series A — $5.0M — Sep 2025
Recent signals
- Sep 16, 2025: Raised $5.0M in Series A
- Sep 16, 2025: AltrixBio Appoints David Pass as Chief Executive Officer
See plans & pricing → Track AltrixBio’s funding, hiring, and signals — with verified contacts — on Fundz.